China Shineway Pharmaceutical
China Shineway Pharmaceutical Group Limited, commonly referred to as Shineway Pharmaceutical, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1997, the company has made significant strides in the development and manufacturing of traditional Chinese medicine and modern pharmaceuticals, with a strong operational presence across Asia and beyond. Shineway Pharmaceutical is renowned for its core products, including herbal medicines and innovative therapeutic solutions, which are distinguished by their quality and efficacy. The company has achieved notable milestones, such as receiving various certifications for its manufacturing processes, solidifying its reputation in the market. With a commitment to research and development, Shineway continues to enhance its product offerings, positioning itself as a leader in the pharmaceutical sector and contributing to the global healthcare landscape.
DitchCarbon Score
How does China Shineway Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China Shineway Pharmaceutical's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
China Shineway Pharmaceutical's reported carbon emissions
In 2022, China Shineway Pharmaceutical reported total carbon emissions of approximately 141,380,020 kg CO2e, which includes 87,499,000 kg CO2e from Scope 1, 30,190,000 kg CO2e from Scope 2, and 23,691,000 kg CO2e from Scope 3 emissions. This data reflects their operations in China. The company has not disclosed specific reduction targets or initiatives, and there are no climate pledges noted in their commitments. The emissions data is cascaded from their parent company, China Shineway Pharmaceutical Group Limited, which is responsible for the overall reporting of emissions. The company has not specified any reduction initiatives or targets under the Science Based Targets initiative (SBTi) or other frameworks. For 2023, while specific emissions data is not available, the company reported a GHG emissions intensity of about 0.00003107 kg CO2e per unit of revenue and approximately 40,840 kg CO2e per employee, indicating a focus on measuring emissions relative to their operational scale. Overall, China Shineway Pharmaceutical's climate commitments appear to be in the early stages, with a need for clearer targets and reduction strategies to align with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Scope 1 | 117,620,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 2 | 8,186,000 | 00,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | 27,604,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
China Shineway Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
